The Effect of Preoperative Dexmedetomidine and Tramadol on Sedation, Pain and Haemodynamics in Haemorrhoids Patients

NCT ID: NCT06860100

Last Updated: 2025-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-17

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the effects of two different pharmacological agents used for analgesic and sedative purposes on perioperative anxiety and intraoperative haemodynamics in haemorrhoidectomy surgeries.

1. How are the effects of Dexmedetomidine and Tramadol on patient anxiety in the preoperative period?
2. Is there any difference in the evaluation of the efficacy of these drugs on postoperative VAS score?
3. How are the effects of the study drugs on intraoperative haemodynamic data?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is planned as a randomised double blind study. The groups will be randomised and divided into two groups by closed envelope method. The person administering the drug and the person who will evaluate the patient will be different and the person making the evaluation will be unaware of which drug is administered to which patient. Preoperative evaluation of the patients included in the study will be performed at least one day before in the Anaesthesiology and Reanimation Polyclinic. Patients between 20-60 years of age, ASA I-II class, who are planned for elective haemorrhoidectomy and whose written and verbal consent is obtained will be included in the study.

Patients who are scheduled for surgery for haemorrhoids and undergo spinal anaesthesia will be included in the case group. However, patients younger than 20 years or older than 60 years, those whose consent could not be obtained, patients with severe renal and hepatic diseases, pregnant women, patients with known allergic response to the agents used and patients with coagulopathy will not be included in the study.

The study is planned as a randomised double blind study. Groups will be randomised by closed envelope method and patients will be divided into 3 groups. The people who administer the drug and the people who evaluate the patient will be different and the evaluator will be unaware of which drug is administered. Preoperative evaluation of the patients included in the study will be performed at least one day before in the Anaesthesiology and Reanimation Polyclinic. A total of 90 patients aged 20-60 years, ASA I-II class, who were planned for elective haemorrhoidectomy and whose written and verbal consent was obtained, will be included in the study.

Patients scheduled for surgery for haemorrhoids and under spinal anaesthesia will be included in the case group. However, patients younger than 20 years or older than 60 years, those whose consent could not be obtained, patients with severe renal and hepatic diseases, pregnant women, patients with known allergic response to the agents used and patients with coagulopathy will not be included in the study.

1. Group C: No drug administration before surgery (30 patients)
2. Group D: Preoperative Dexmedetomidine group (30 patients)
3. Group T: Preoperative Tramadol group (30 patients) STAI anxiety scale, VAS score and pain assessment will be applied to all groups in the preoperative evaluation room.

1-Group C-(Control group): no preoperative drug administration 2-Group D-(Dexmedetomidine group): 1 mcg/kg dexmedetomidine iv infusion 10 minutes loading 3-Group T-(Tramadol group): 1 mg/kg tramadol iv infusion 10 minutes loading All of the groups will undergo subarachnoid saddle block with 1 cc 0.5% bupivacaine heavy in the L4-L5 interval.

Intraoperative haemodynamic parameters (noninvasive blood pressure, SpO2 and heart rate) and sedation requirement will be recorded. For sedation, 1 mg midazolam will be administered intravenously to all groups. Patients will be excluded from the study if the total intraoperative sedation dose exceeds 5 mg. All data will be collected and statistically analysed and the results obtained will be interpreted.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia Sedation Anxiety Intraoperative Haemodynamics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deksmedetomidine Group

Preoperative 1 mcg/kg dexmedetomidine iv infusion 10 minutes loading

No interventions assigned to this group

Tramadol Group

Preoerative 1 mg/kg tramadol iv infusion 10 min loading

No interventions assigned to this group

Control group

no medication before surgery

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA I-II
* 20-60 years
* haemorrhoidectomy to be performed
* written Consent

Exclusion Criteria

* ASA III and above Under 20 years old - over 60 years old,
* those who cannot be taken written consent
* severe renal and hepatic disease,
* pregnants,
* those with a known allergic response to the agents used
* patients with coagulopathy
Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yuzuncu Yil University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Arzu Esen Tekeli

Associated Professor Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Van Yuzuncu Yil University School of Medicine Department of Anesthesiology and Reanimation

Van, Tuşba, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19.11.2024/03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dexmedetomidine and Remifentanil in NORA
NCT06403670 COMPLETED PHASE4